BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37680128)

  • 1. Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease.
    Zhang F; Zhang M; Yuan X; Tao Y; Wang J
    Curr Pharm Des; 2023; 29(26):2091-2100. PubMed ID: 37680128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
    Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
    Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients.
    Zhang T; Yang H; Sun B; Yao F
    Aging (Albany NY); 2021 Jan; 13(3):3819-3842. PubMed ID: 33428598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
    Bin Y; Ding P; Liu L; Tong F; Dong X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9051-9070. PubMed ID: 37169931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP12 serves as an immune cell-related marker of disease status and prognosis in lung squamous cell carcinoma.
    Zhang W; Li GS; Gan XY; Huang ZG; He RQ; Huang H; Li DM; Tang YL; Tang D; Zou W; Liu J; Dang YW; Chen G; Zhou HF; Kong JL; Lu HP
    PeerJ; 2023; 11():e15598. PubMed ID: 37601247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.
    Guo Q; Wu CY; Jiang N; Tong S; Wan JH; Xiao XY; Mei PY; Liu HS; Wang SH
    Front Immunol; 2022; 13():986447. PubMed ID: 36544782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exploration of the Perturbation of PKIG in Lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].
    Liu Q; Li H; Li B; Ren M; Li Z; Chen Y; Zheng Z; Meng Y; Feng H
    Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):523-537. PubMed ID: 37653016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGN as a prognostic biomarker with immune infiltration and ceRNA in lung squamous cell carcinoma.
    Liao Y; Cheng W; Mou R; Li X; Jia Y
    Sci Rep; 2023 May; 13(1):7553. PubMed ID: 37161020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
    Lai J; Lin X; Zheng H; Xie B; Fu D
    BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIMK2 Is a Novel Prognostic Biomarker and Correlates With Tumor Immune Cell Infiltration in Lung Squamous Cell Carcinoma.
    Su Y; Xu B; Shen Q; Lei Z; Zhang W; Hu T
    Front Immunol; 2022; 13():788375. PubMed ID: 35273591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of immune subtypes and overall survival in lung squamous cell carcinoma.
    Su X; Gao H; Qi Z; Xu T; Wang G; Luo H; Cheng P
    Curr Med Res Opin; 2023 Feb; 39(2):289-298. PubMed ID: 36245361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.